An unusual complication of a long-acting injectable antipsychotic: deep venous thrombosis caused by olanzapine pamoate

References

• Baruch N, Das M, Sharda A, Basu A, Bajorek T, Ross CC, et al. An evaluation of the use of olanzapine pamoate depot injection in seriously violent men with schizophrenia in a UK high-security hospital. Ther Adv Psychopharmacol. 2014;4(5):186–192. doi: 10.1177/2045125314531982
   Google Scholar
• Muench J, Hamer AM. Adverse effects of anti-psychotic medications. Ann Fam Physician. 2010;81(5):617–622.
   PubMed Web of Science ®Google Scholar
• Barnes TRE, Cursori DA. Long-term depot antipsychotics. A risk-benefit assessment. Drug Saf. 1994;10(6):464–479. doi: 10.2165/00002018-199410060-00005
   PubMed Web of Science ®Google Scholar
• Lensing AWA, Prandoni P, Prins MH, et al. Deep-vein thrombosis. Lancet. 1999;353(9151):479–485. doi: 10.1016/S0140-6736(98)04298-6
   PubMed Web of Science ®Google Scholar
• Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet. 2005;365(9465):1163–1174. doi: 10.1016/S0140-6736(05)71880-8
   PubMed Web of Science ®Google Scholar
• Koksoy C, Yilmaz MF, Basbug HS, Calik ES, Erkut B, Kaygın MA, et al. Pharmacomechanical thrombolysis of symptomatic acute and subacute deep venous thrombosis with a rotational thrombectomy device. J Vasc Interv Radiol. 2014;25(12):1895–1900. doi: 10.1016/j.jvir.2014.08.018
   PubMed Web of Science ®Google Scholar
• Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation. 1996;93(12):2212–2245. doi: 10.1161/01.CIR.93.12.2212
   Web of Science ®Google Scholar
• Hagg S, Jonsson AK, Spigset O. Risk of venous thromboembolism due to antipsychotic drug therapy. Expert Opin Drug Saf. 2009;8(5):537–547. doi: 10.1517/14740330903117271
   PubMed Web of Science ®Google Scholar
• Hagg S, Spigset O, Soderstrom TG. Association of venous thromboembolism and clozapine. Lancet. 2000;355(9210):1155–1156. doi: 10.1016/S0140-6736(00)02066-3
   PubMed Web of Science ®Google Scholar
• Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245. doi: 10.1038/clpt.1981.154
   PubMed Web of Science ®Google Scholar
• Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs. 2004;64(7):701–723. doi: 10.2165/00003495-200464070-00003
   PubMed Web of Science ®Google Scholar
• Hagg S, Bate A, Stahl M, et al. Associations between venous thromboembolism and antipsychotics. Drug Saf. 2008;31(8):685–694. doi: 10.2165/00002018-200831080-00005
   Web of Science ®Google Scholar
• Hagg S, Spigset O. Antipsychotic-induced venous thromboembolism. CNS Drugs. 2002;16(11):765–776. doi: 10.2165/00023210-200216110-00005
   Web of Science ®Google Scholar
• Liperoti R, Pedone C, Lapane KL, et al. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med. 2005;165(22):2677–2682. doi: 10.1001/archinte.165.22.2677
   Google Scholar
• Waage IM, Gedde-Dahl A. Drug points: pulmonary embolism possibly associated with olanzapine treatment [letter]. Br Med J. 2003;327(7428):1384. doi: 10.1136/bmj.327.7428.1384
   Web of Science ®Google Scholar
• del Conde I, Goldhaber SZ. Pulmonary embolism associated with olanzapine. Thromb Haemost. 2006;96(5):690–691.
   Web of Science ®Google Scholar
• Lindenmayer JP. Long-acting injectable antipsychotics: focus on olanzapine pamoate. Neuropsychiatr Dis Treat. 2010;6(6):261–267. doi: 10.2147/NDT.S3072
   Google Scholar
• Kurtz H, Bergstrom R, McDonnell DP, et al. Pharmocokinetics (PK) of multiple doses of olanzapine long acting injection (OLAI), an intramuscular (IM) depot formulation of olanzapine (OLZ), in stabilized patients with schizophrenia. Biol Psychiatry. 2008;63(7):288S.
   Web of Science ®Google Scholar
• Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry. 2009;195:S13–S19. doi: 10.1192/bjp.195.52.s13
   Web of Science ®Google Scholar
• Detke HC, Zhao F, Garhyan P, et al. Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching. Int Clin Psychopharmacol. 2011;26(1):35–42. doi: 10.1097/YIC.0b013e32834093d1
   PubMed Web of Science ®Google Scholar
• Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med. 2004;117(1):19–25. doi: 10.1016/j.amjmed.2004.01.018
   PubMed Web of Science ®Google Scholar
• Kredentser MS, Martens PJ, Chochinov HM, et al. Cause and rate of death in people with schizophrenia across the lifespan: a population-based study in Manitoba, Canada. J Clin Psychiatry. 2014;75(2):154–161. doi: 10.4088/JCP.13m08711
   PubMed Web of Science ®Google Scholar
• Choi J, Medalia A. Intrinsic motivation and learning in a schizophrenia spectrum sample. Schizophr Res. 2010;118(1–3):12–19. doi: 10.1016/j.schres.2009.08.001
   Web of Science ®Google Scholar
• Docx L, Sabbe B, Provinciael P, et al. Quantitative psychomotor dysfunction in schizophrenia: a loss of drive, impaired movement execution or both? Neuropsychobiology. 2013;68(4):221–227. doi: 10.1159/000355293
   Web of Science ®Google Scholar
• Hsu WY, Lane HY, Lin CL, et al. A population-based cohort study on deep vein thrombosis and pulmonary embolism among schizophrenia patients. Schizophr Res. 2015;162(1):248–252. doi: 10.1016/j.schres.2015.01.012
   Web of Science ®Google Scholar
• Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. Br Med J. 2010;341:c4245. doi: 10.1136/bmj.c4245
   PubMed Web of Science ®Google Scholar